Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Show Display Options
Download search resultsDownload the search results for:
Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego (9 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Conditions: Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Arteriosclerosis;   Arterial Occlusive Diseases;   Vascular Diseases
Intervention: Procedure: CorPath-assisted Percutaneous Coronary Intervention
2 Recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
3 Recruiting A Complex Contraception Registry
Conditions: Diabetes;   Cardiovascular Disease;   Epilepsy;   Migraine;   Neurological Disorders;   Cancer;   Bariatric Surgery Candidate;   Organ or Tissue Transplant; Complications;   Lupus Erythematosus, Systemic;   Other Hematologic Conditions;   Other Venous Embolism and Thrombosis
Intervention:
4 Recruiting Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Condition: Abdominal Aortic Aneurysm (AAA)
Intervention: Device: Nellix System
5 Recruiting Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Condition: Hereditary Angioedema
Interventions: Drug: DX-2930;   Drug: Placebo
6 Recruiting Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
7 Recruiting SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
8 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
9 Recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Conditions: Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention: Genetic: cytogenetic analysis

Indicates status has not been verified in more than two years